

**CENTER FOR DIGESTIVE DISEASES
& CARY ENDOSCOPY CENTER
REMICADE INFUSIONS**

Remicade is a monoclonal anti-body therapy approved for the treatment of patients with moderately to severely active ulcerative colitis (UC) who haven't responded well to conventional therapies. Remicade can provide long-lasting control of ulcerative colitis flares and symptoms.

Remicade is administered as a 2-hour intravenous infusion. There will also be a period of pre-infusion preparation and post-treatment monitoring by a nurse. Remicade treatment is typically recommended every eight weeks after the initial three starter doses.

Remicade is non-sedating. However, some patient's require anti-histimine co-therapy to prevent side effects. The co-therapy a patient receives it will determine whether or not you may be able to drive after your treatment and continue with your normal schedule.

Remicade can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steriods in patients with moderately to severely active ulcerative colitis and who have not responded well to other therapies.